189 related articles for article (PubMed ID: 37648262)
1. NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells.
Hussein BA; Kristenson L; Pesce S; Wöhr A; Tian Y; Hallner A; Brune M; Hellstrand K; Tang KW; Bernson E; Thorén FB
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648262
[TBL] [Abstract][Full Text] [Related]
2. The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.
Hallner A; Bernson E; Hussein BA; Ewald Sander F; Brune M; Aurelius J; Martner A; Hellstrand K; Thorén FB
Blood; 2019 Mar; 133(13):1479-1488. PubMed ID: 30647027
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
[TBL] [Abstract][Full Text] [Related]
4. Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia.
Hussein BA; Hallner A; Wennström L; Brune M; Martner A; Hellstrand K; Bernson E; Thorén FB
Front Immunol; 2021; 12():796072. PubMed ID: 34956230
[TBL] [Abstract][Full Text] [Related]
5. [Expression of NKG2D and NKG2A with their ligands MHC-I A/B and HLA-E in acute leukemia patients and its significance].
Ge SJ; Duan LN; Luo Y; Suo TL; Lu CR; Tang J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):312-6. PubMed ID: 21518478
[TBL] [Abstract][Full Text] [Related]
6. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
Bernson E; Hallner A; Sander FE; Wilsson O; Werlenius O; Rydström A; Kiffin R; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
Leukemia; 2017 Dec; 31(12):2552-2559. PubMed ID: 28529313
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory NKG2A and activating NKG2D and NKG2C natural killer cell receptor genes: susceptibility for rheumatoid arthritis.
Park KS; Park JH; Song YW
Tissue Antigens; 2008 Oct; 72(4):342-6. PubMed ID: 18700876
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway.
Wu HY; Li KX; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Huang YX
Int Immunopharmacol; 2022 Mar; 104():108497. PubMed ID: 34999394
[TBL] [Abstract][Full Text] [Related]
9. The effect of mifepristone on the peripheral blood natural killer cell's cytotoxicity and expression of CD94/NKG2A and NKG2D during the implantation phase.
Chen XY; Zhuang YL; Li L; Zhang WW; Huang LL
Fertil Steril; 2010 May; 93(8):2615-20. PubMed ID: 19880106
[TBL] [Abstract][Full Text] [Related]
10. HLA-B*44 and the Bw4-80T motif are associated with poor outcome of relapse-preventive immunotherapy in acute myeloid leukemia.
Komic H; Hallner A; Hussein BA; Badami C; Wöhr A; Hellstrand K; Bernson E; Thorén FB
Cancer Immunol Immunother; 2023 Nov; 72(11):3559-3566. PubMed ID: 37597015
[TBL] [Abstract][Full Text] [Related]
11. Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts.
Nielsen N; Pascal V; Fasth AE; Sundström Y; Galsgaard ED; Ahern D; Andersen M; Baslund B; Bartels EM; Bliddal H; Feldmann M; Malmström V; Berg L; Spee P; Söderström K
Immunology; 2014 Aug; 142(4):581-93. PubMed ID: 24673109
[TBL] [Abstract][Full Text] [Related]
12. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.
Diermayr S; Himmelreich H; Durovic B; Mathys-Schneeberger A; Siegler U; Langenkamp U; Hofsteenge J; Gratwohl A; Tichelli A; Paluszewska M; Wiktor-Jedrzejczak W; Kalberer CP; Wodnar-Filipowicz A
Blood; 2008 Feb; 111(3):1428-36. PubMed ID: 17993609
[TBL] [Abstract][Full Text] [Related]
13. Circulating NKG2A-NKG2D+ CD56dimCD16+ Natural Killer (NK) Cells as Mediators of Functional Immunosurveillance in Kidney Transplant Recipients.
Zhu L; Karakizlis H; Weimer R; Morath C; Ekpoom N; Ibrahim EH; Opelz G; Daniel V
Ann Transplant; 2020 Dec; 25():e925162. PubMed ID: 33349627
[TBL] [Abstract][Full Text] [Related]
14. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-18 synergism with interleukin-2 in cytotoxicity and NKG2D expression of human natural killer cells.
Qi YY; Lu C; Ju Y; Wang ZE; Li YT; Shen YJ; Lu ZM
Asian Pac J Cancer Prev; 2014; 15(18):7857-61. PubMed ID: 25292077
[TBL] [Abstract][Full Text] [Related]
16. NKG2A Expression Is Not
Mahaweni NM; Ehlers FAI; Sarkar S; Janssen JWH; Tilanus MGJ; Bos GMJ; Wieten L
Front Immunol; 2018; 9():1415. PubMed ID: 29988376
[TBL] [Abstract][Full Text] [Related]
17. Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation.
Machuldova A; Holubova M; Caputo VS; Cedikova M; Jindra P; Houdova L; Pitule P
Front Immunol; 2021; 12():651751. PubMed ID: 33868289
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells.
Sarkar S; Germeraad WT; Rouschop KM; Steeghs EM; van Gelder M; Bos GM; Wieten L
PLoS One; 2013; 8(5):e64835. PubMed ID: 23724099
[TBL] [Abstract][Full Text] [Related]
19. Permanent silencing of NKG2A expression for cell-based therapeutics.
Figueiredo C; Seltsam A; Blasczyk R
J Mol Med (Berl); 2009 Feb; 87(2):199-210. PubMed ID: 19002424
[TBL] [Abstract][Full Text] [Related]
20. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]